Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 13Recruiting 6Unknown 3Active not recruiting 3Terminated 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Lung Neoplasms 8Mesothelioma, Malignant 4Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Advanced Non-squamous Non-small-cell Lung Cancer 2Uterine Cervical Neoplasms 1Solitary Fibrous Tumor, Pleural 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Head and Neck Neoplasms 1Glioma 1Esophagogastric Cancer 1Colorectal Neoplasms 1Advanced Solid Tumors 1

Interventions

Oxaliplatin 20Fluorouracil 20Leucovorin 19Bevacizumab 16Cetuximab 13Irinotecan 12Capecitabine 8regorafenib 5Radiotherapy 5Nivolumab 5Drug Therapy 5aflibercept 4Radiosurgery 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Chemotherapy, Adjuvant 4Biopsy 4pembrolizumab 3durvalumab 3atezolizumab 3Specimen Handling 3Folfox protocol 3Cyclophosphamide 3trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2poly(I).poly(c12,U) 2futuximab 2fludarabine 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Neoplasms × Pemetrexed × Clear all
NCT03843853 2022-07-25

Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡